SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893917.
  • 2
    Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8: 8694.
  • 3
    Maehara Y, Kakeji Y, Oda S, Baba H, Sugimachi K. Tumor growth patterns and biological characteristics of early gastric carcinoma. Oncology 2001; 61: 10212.
  • 4
    Noto JM, Peek RM. The role of microRNAs in Helicobacter pylori pathogenesis and gastric carcinogenesis. Front Cell Infect Microbiol 2011; 1: 21.
  • 5
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 3149.
  • 6
    Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gann 1968; 59: 2518.
  • 7
    Saito K, Shimoda T. The histogenesis and early invasion of gastric cancer. Acta Pathol Jpn 1986; 36: 130718.
  • 8
    Tatematsu M, Ichinose M, Miki K, Hasegawa R, Kato T, Ito N. Gastric and intestinal phenotypic expression of human stomach cancers as revealed by pepsinogen immunohistochemistry and mucin histochemistry. Acta Pathol Jpn 1990; 40: 494504.
  • 9
    Reis CA, Davvid L, Correa P et al. Intestinal metaplasia of human stomach displays distinct pattern of mucin (MUC1, MUC2, MUC5AC, MUC6) expression. Cancer Res 1999; 59: 10037.
  • 10
    De Bolos C, Garrido M, Real FX. MUC6 apomucin shows a distinct normal tissue distribution that correlates with Lewis antigen expression in the human stomach. Gastroenterology 1995; 109: 72334.
  • 11
    Carrato C, Balague C, De Bolos C et al. Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology 1994; 107: 16072.
  • 12
    Baldus SE, Zirbes TK, Engel S et al. Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1and MUC2 with the histopathological subtype and prognosis of gastric carcinomas. Int J Cancer 1998; 79: 1338.
  • 13
    Endoh Y, Tamura G, Motoyama T, Ajioka Y, Watanabe H. Well-differentiated adenocarcinoma mimicking complete-type intestinal metaplasia in the stomach. Hum Pathol 1999; 30: 82632.
  • 14
    Sato Y, Itoh F, Hinoda Y et al. Expression of CD10/neural endopeptidase in normal and malignant tissues of the human stomach and colon. J Gastroenterol 1996; 31: 127.
  • 15
    Namikawa T, Hanazaki K. Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma. World J Gastroenterol 2010; 16: 46349.
  • 16
    Mizoshita T, Tsukamoto T, Nakanishi H et al. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol 2003; 129: 72734.
  • 17
    Tajima Y, Shimoda T, Nakanishi Y et al. Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions. Oncology 2001; 61: 21220.
  • 18
    Zheng H, Takahashi H, Nakajima T et al. MUC6 down–regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays. J Cancer Res Clin Oncol 2006; 132: 81723.
  • 19
    Tajima Y, Yamazaki K, Nishino N et al. Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immnohistochemical analysis of 213 lesions. Br J Cancer 2004; 91: 13428.
  • 20
    Roviello F, Marrelli D, Manzoni G et al. Prospective study of peritoneal reccurence after curative surgery for gastric cancer. Br J Surg 2003; 90: 11139.
  • 21
    Ishihara K, Kurihara M, Goso Y et al. Peripheral α-linked N-accetylglucosamine on the carbohydrate moiety of mucin derived from mammalian gastric glnand mucous cell: epitope recognized by a newly characterized monoclonal antibody. Biochem J 1996; 318(Pt 2): 228.
  • 22
    Zhang MX, Nakayama J, Hidaka E et al. Immunohistochemical demonstration of α1,4-N-accetylglucosaminyltransferase that forms GlcNAcα1,4Galβ residues in human gastrointestinal mucosa. J Histochem Cytochem 2001; 49: 58796.
  • 23
    Nakayama J, Yeh JC, Misra AK, Ito S, Katsuyama T, Fukuda M. Expression cloning of a human α1,4-N-acetylglucosaminyltransferase that forms GlcNAcα1[RIGHTWARDS ARROW]4Galβ[RIGHTWARDS ARROW]R, a glycan specifically expressed in the gastric gland mucous cell-type mucin. Proc Natl Acd Sci USA 1999; 96: 89916.
  • 24
    Kawakubo M, Ito Y, Okimura Y et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004; 305: 10036.
  • 25
    Karasawa F, Shiota A, Goso Y et al. Essential role of gastric gland mucin in preventing gastric cancer in mice. J Clin Invest 2012; 122: 92334.
  • 26
    Nakajima K, Ota H, Sano K et al. Expression of gastric gland mucous cell-type mucin in normal and neoplastic human tissues. J Histochem Cytocem 2003; 51: 168998.
  • 27
    Shiroshita H, Watanabe H, Ajioka Y, Watanabe G, Nishikura K, Kitano S. Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains. Pathol Int 2004; 54: 31121.
  • 28
    Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 14th edn. Tokyo, Japan: Kanehara, 2010.
  • 29
    Machida E, Nakayama J, Amano J, Fukuda M. Clinicopathological significance of core 2 β1,6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization. Cancer Res 2001; 61: 222631.
  • 30
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 31
    Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 139.
  • 32
    Ota H, Hayama M, Nakayama J et al. Cell lineage specificity of newly raised monoclonal antibodies against gastric mucins in normal, metaplastic, and neoplastic human tissues and their application to pathology diagnosis. Am J Clin Pathol 2001; 115: 6979.
  • 33
    Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010; 21: 2739.
  • 34
    Ohta M, Kitadai Y, Tanaka S et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 2003; 22: 7738.
  • 35
    Verbeke H, Geboes K, Van Damme J, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 2012; 1825: 11729.
  • 36
    Nakayama T, Yoshizaki A, Izumida S et al. Expression of interleukin-11 (IL-11) receptor α in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. Int J Oncol 2007; 30: 82533.
  • 37
    Mohri Y, Miki C, Tanaka K et al. Clinical correlations and prognostic relevance of tissue angiogenic factors in patients with gastric cancer. Clin Oncol (R Coll Radiol) 2012; 24: 6106.
  • 38
    Toki F, Takahashi A, Aihara R et al. Relationship between clinicopathological features and mucin phenotypes of advanced gastric adenocarcinoma. World J Gastroenterol 2010; 16: 276470.
  • 39
    Reis CA, David L, Carvalho F et al. Immunohistochemical study of the expression of MUC6 mucin and co-expression of other secreted mucins (MUC5AC and MUC2) in human gastric carcinomas. J Histochem Cytochem 2000; 48: 37788.
  • 40
    Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 2001; 92: 142734.